GN-HEARING
28.10.2021 09:02:09 CEST | Business Wire | Press release
GN Hearing, the global leader in hearing aid innovation, today announced that ReSound ONE ™ hearing aids will offer hands-free phone and FaceTime calls from iPhone and iPad. ReSound ONE users will be able to answer calls with just a tap on their hearing aids and enjoy conversations with outstanding sound quality — all without ever having to take their device out of their pocket. The new technology is a great solution for conversations while multitasking, for example, when cooking, carrying groceries, being at work, or when the iPhone or iPad is simply out of reach.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005221/en/
Musician Sivu, who lives with hearing loss, has been trying out ReSound ONE with the hands-free technology: “Like everyone else I use my iPhone a lot to keep in touch with family and friends that I can’t see in person. With this new technology, it makes it a lot easier to call people without having to stop what I’m doing and hold my phone to talk. I don’t have to put everything down, which has proved useful in a recording studio environment. I can use my iPhone exactly the same way as I did before my hearing deteriorated which is extremely important to me.”
When connecting in person is challenging, making communication more accessible through technology is crucial, particularly for those living with hearing loss. Utilizing Apple’s recent iOS15 and iPadOS 15 software update with added support for bi-directional hearing devices, ReSound ONE hearing aids greatly improve the hearing experience for iPhone and iPad users with more efficient battery management, reliable audio streaming, and entirely new hands-free calling. ReSound ONE hearing aid users can stream all day long with confidence, knowing they are connected to the world around them in the most intuitive and natural way – something ReSound champions with their Organic Hearing philosophy.
In 2013 GN Hearing introduced the first Made for iPhone hearing aids that offered streaming directly from Apple devices. The new software update represents the latest advancement in Made for iPhone connectivity for hearing aids – an entirely new addition for the direct streaming of iPhone and iPad audio. GN Hearing continues to put the needs of people with hearing loss at the centre of innovation with these new standards in connectivity.
GN Hearing CEO and President, Gitte Aabo, explains: “At GN Hearing, we’re incredibly proud to continue to deliver simple solutions with best-in-class user experiences across Apple devices. When we work in harmony, we can make a real difference to people’s day-to-day lives.”
GN Hearing’s ReSound ONE hearing aids are an authorized Made for iPhone accessory and have been certified to meet Apple performance standards. ReSound ONE hearing aids are compatible with iPhone 11, iPhone 11 Pro, iPhone 11 Pro Max, and later. You can also use these hearing aids with iPad Pro 12.9-inch (5th generation), iPad Pro 11-inch (3rd generation), iPad Air (4th generation), and iPad mini (6th generation).
To enable hands-free calling on iPhone or iPad, ReSound ONE and Beltone Imagine users will get a device software update from December 2021. In addition, all ReSound and Beltone hearing aids feature leading streaming options including direct streaming from iPhone and a suite of wireless accessories. For further information, visit the ReSound Newsroom and learn about GN’s Organic Hearing philosophy.
NOTES TO EDITORS
About ReSound
ReSound hearing aids, available from leading hearing care professionals, continue to set worldwide standards for quality and intuitive technology to help people with hearing loss communicate better than ever before. ReSound was the first hearing aid brand to be Made for iPhone, bringing direct streaming from hearing aids into the iPhone era. It also pioneered the development of 2.4 GHz wireless technology and made it possible to receive advanced at-home hearing care during COVID-19. The recent introduction of a new class of hearing technology with ReSound ONE demonstrates that ReSound is the undisputed innovation leader putting people with hearing loss at the center. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com , get to know our innovation and leadership , and connect with us on LinkedIn and Facebook .
© 2021 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad and FaceTime are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc., registered in the U.S. and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005221/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom